Here you will find current and archived press releases, listings of upcoming events, and news coverage about the company and some of its projects and initiatives.




Rejoignez-nous lors du 33ème séminaire de génétique clinique les 2 et 3 février 2023 à Angers. Thomas Bolzec et Mira Ayadi vous attendent avec plaisir sur notre stand pour discuter de vos projets de génomique. N’hésitez pas à les contacter pour prendre rendez-vous :

#content-main{display:none} For full functionality (…)  » 

IntegraGen reports €12.6m in revenues for 2022 representing 16% growth compared to 2021 and a cash position of €4.5m

Growth supported by the high-throughput genomic sequencing laboratory in Evry Continued sequencing activities on platforms operated on behalf of third parties supported by new clinical research projects in oncology

EVRY, FRANCE, FRIDAY JANUARY 13TH 2023, 7.30AM CET – IntegraGen (FR0010908723 – ALINT), an OncoDNA Group company specializing in the decryption of (…)  » 

IntegraGen reports strong revenues growth of 35% with profitability improvement

Better profitability despite the inflation Confirmed growth outlook for the 2022 financial year Increase in services provided to platforms operated on behalf of third parties

EVRY, FRANCE, TUESDAY OCTOBER 18TH 2022, 7.30AM – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), IntegraGen, a company specializing in the decryption (…)  » 

IntegraGen reports 6.4 M€ in revenues for the first half of 2022 representing 34% growth compared to H1 2021. Cash position of 4.5 M€.

Continued sustained growth associated with the company’s sequencing platform in Évry and long-term contracts Strong revenue growth linked with microbiology sequencing

Evry, France, Wednesday July 13th 2022, 7.30am – IntegraGen (FR0010908723 – ALINT ), an OncoDNA Group company specializing in the decryption of the human genome which performs (…)  » 

IntegraGen and BIOASTER sign a partnership agreement in genomics and transcriptomics

IntegraGen and BIOASTER have been collaborating for several years in the context of genomic and transcriptomic analyses. Driven by a desire to strengthen this relationship further, the two entities have entered into a long-term partnership agreement (Master Research Service Agreement). This agreement will facilitate and accelerate exchanges between (…)  » 

Interview with CEO Bernard Courtieu

Bernard Courtieu CEO OncoDNA

Ditsa Keren is a technology blogger and entrepreneur with a strong passion for biology, ecology and the environment. She spoke to our CEO Bernard Courtieu to hear about the latest advancements in precision medicine and the promise we bring to oncology physicians and researchers.

Discover the entire interview on (…)  »